Thu 20 Aug 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Ensure the website is using the HTTPS protocol.
Registered with the Digital Government Authority under number:
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| Ketamine for Acute Painful Crisis in Sickle Cell Disease Patients: Prospective Randomized Control trial | King Fahad Hospital of the University | Completed | Ketamine | 3 | 2016-01-042 -Version 02 | King Fahad Hospital of the University |
| A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06687234 AS ADD-ON THERAPY TO INFLIXIMAB IN ACTIVE ULCERATIVE COLITIS SUBJECTS WHO ARE NOT IN REMISSION (BUILD UC) | Pfizer | Ongoing | PF-06687234 | 2 | B7581002 | King Abdulaziz Medical City NG (Riyadh), King Abdulaziz University Hospital (Jeddah), King Khalid University Hospital (Riyadh) |
| An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF)DELIVER - Dapagliflozin Evaluation to Improve the LIVEs of Patients with PReserved Ejection Fraction Heart Failure | AstraZeneca | Ongoing | Dapagliflozin | 3 | D169CC00001 | King Khalid University Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz University Hospital (Jeddah), Saud Al-Babtain Cardiac Center (Dammam), King Abdulaziz Medical City NG (Riyadh), King Fahad Medical City (Riyadh) |
| "A Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study to DemonstrateEfficacy and Safety of A4250 in Children with Progressive Familial IntrahepaticCholestasis Types 1 and 2 (PEDFIC 1)" | Albireo | Ongoing | A4250 | 3 | A4250-005 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| Phase 2, Multi-Center, Double-Blind, Randomized, 2-Arm, Parallel Study to Assess the Efficacy and Safety of Ryanodex (EGL-4104) as Adjuvant Treatment in Subjects with Exertional Heat Stroke (EHS) | Eagle Pharmaceuticals | Ongoing | Dantrolene | 2 | EGL-4104-C-1801 | King Faisal General Hospital (Makkah), Mina Al-Jisr Hospital, Mina Al-Wadi Hospital, Mina Al-Shari' Al-Jadid Hospital |
| A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma (NAVIGATOR) | AstraZeneca | Ongoing | Tezepelumab | 3 | D5180C00007 | King Abdulaziz University Hospital (Jeddah), King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Jeddah) |
| A two part seamless, open label, multi-center study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in infants with type 1 spinal muscular atrophy. | Roche | Terminated | Risdiplam | 2 | BP39056 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| The effect of cinnamon supplementation on ovulation induction in women with polycystic ovary syndrome, Jeddah 2018: Randomized Double-Blind Placebo-controlled trial | King Abdulaziz University (Jeddah) | Ongoing | Cinnamon | 3 | 100-18 | King Abdulaziz University Hospital (Jeddah) |
| "AURIGA / An observationAl stUdy pRogram toInvestiGate the effectiveness of intravitreal Aflibercept indiabetic macular edema and/or macular edema secondary toretinal vein occlusion in a real world setting." | Bayer | Ongoing | Aflibercept | 4 | 191 57 | King Faisal Specialist Hospital and Research Center (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah), King Khalid University Hospital (Riyadh) |
| Apixaban in Patients with Left Ventricular Thrombus, CLEAN-LV Study | Saud Al Babtain Cardiac Center | Ongoing | Apixaban | 4 | 2018-08 | Saud Al-Babtain Cardiac Center (Dammam)N/A |
Last update date: 08/05/2025 at 03:17 PM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.